1. Home
  2. ADSE vs ALLO Comparison

ADSE vs ALLO Comparison

Compare ADSE & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ADSE

ADS-TEC ENERGY PLC

HOLD

Current Price

$10.46

Market Cap

577.8M

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.48

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADSE
ALLO
Founded
1980
2017
Country
Ireland
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
577.8M
539.4M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
ADSE
ALLO
Price
$10.46
$2.48
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$8.36
AVG Volume (30 Days)
3.7K
4.5M
Earning Date
01-01-0001
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$219.58
N/A
Revenue Next Year
N/A
$141,204.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.89
$0.86
52 Week High
$15.18
$2.80

Technical Indicators

Market Signals
Indicator
ADSE
ALLO
Relative Strength Index (RSI) 43.22 57.05
Support Level $9.55 $1.01
Resistance Level $12.79 $2.80
Average True Range (ATR) 0.78 0.19
MACD -0.10 -0.03
Stochastic Oscillator 15.29 48.33

Price Performance

Historical Comparison
ADSE
ALLO

About ADSE ADS-TEC ENERGY PLC

ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: